Market misjudgment? How did Shenzhou Holdings (00861) perform in the first quarter?
The main business has repeatedly signed large orders, and big data and overseas business are growing strongly
Earnings Growth Outpaced the Notable 53% Return Delivered to Meitu (HKG:1357) Shareholders Over the Last Year
Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than that by picking better than average stocks (as part of a diversified portfolio)
Research Nuggets | CICC: Raising CNOOC's target price to HK$24, raising profit forecast for this year and next two years
According to a research report published by CICC, CNOOC's revenue for the first quarter increased 14% year-on-year, and net profit increased by 23.7%. Production exceeded expectations, driving quarterly performance higher than market expectations. During the period, CNOOC's oil and gas production increased by 9.9% year-on-year to 180 million barrels of oil equivalent. China's domestic oil and gas production increased 6.9%, and overseas production increased 16.9%. The expected increase in CICC's production is mainly driven by early commissioning of the domestic Suizhong 36-1/Luda 5-2 oil field during the second adjustment period, as well as an increase in output from the Canadian oil sands project. Looking ahead, CICC remains optimistic about CNOOC's production growth and is expected to exceed 2 for the whole year
Great Week for RemeGen Co., Ltd. (HKG:9995) Institutional Investors After Losing 33% Over the Previous Year
Key Insights Given the large stake in the stock by institutions, RemeGen's stock price might be vulnerable to their trading decisions The top 8 shareholders own 51% of the company 12% of RemeGen
The Recent 5.6% Gain Must Have Brightened Top Key Executive Jianrong Ma's Week, Shenzhou International Group Holdings Limited's (HKG:2313) Most Bullish Insider
Key Insights Insiders appear to have a vested interest in Shenzhou International Group Holdings' growth, as seen by their sizeable ownership The top 3 shareholders own 51% of the company Institut
Does This Valuation Of Everest Medicines Limited (HKG:1952) Imply Investors Are Overpaying?
Key Insights The projected fair value for Everest Medicines is HK$20.13 based on 2 Stage Free Cash Flow to Equity Everest Medicines is estimated to be 22% overvalued based on current share price of